Technological advancements to drive growth of the global artificial pancreas device system (APDS) market

Artificial Pancreas Device System (APDS) – Putting the Ease in Diabetes Management

Administering insulin on daily basis is cumbersome for type 1 diabetes (T1D) patients in a busy lifestyle. While devices such as insulin pumps, pens, and jet injectors have made living with diabetes less stressful by ridding users of relatively painful insulin delivering devices such as needles and syringes. Juvenile Diabetes Research Foundation (JDRF) is working in collaboration with many industry players such as Medtronic, Inc., Johnson & Johnson, and Tandem Diabetes Care, Inc. to develop innovative insulin and glucose monitoring systems/devices.

Artificial pancreas is the outcome of these collaborations which is also encouraged for use by the FDA. Artificial pancreas device system (APDS) consists of an insulin pump, sensor, transmitter, and a receiver. MiniMed 530G from Medtronic, Inc. was the first artificial pancreas device system (APDS) approved by FDA. This threshold suspend device system enables temporary suspension of insulin delivery when the glucose level is lower than the threshold level. Another system, Medtrum’s P6 Easy Touch Disposable Pump is a semi-closed loop artificial pancreas that is under clinical trials in Europe. Many such systems are under clinical trials and expected to be launched in near future in the global artificial pancreas device system (APDS) market. Developed economies in North America, Europe and Pacific region would be the potential regional opportunities for this novel system in the global artificial pancreas device system (APDS) market.

Category Product Company/Institute Status Expected launch
Threshold Suspended Device Systems t:slim Tandem XX XX
Treat to Range/Control to Range (TTR/CTR) Animas pump Animas Corporation XX XX
Treat to Target/ Control to Target (TTR/CTT) Insulin-only iLet Beta Bionics FDA submission by 2017 end XX
XX XX XX XX
XX XX XX XX
Hybrid systems MiniMed 670G Medtronic FDA Approved Apr-17
XX XX XX  
XX XX XX XX
Bi-hormonal systems iLet Beta Bionics FDA submission potentially in 2019.  
XX XX XX  
XX XX XX  

The global artificial pancreas device system (APDS) market was valued at US$ 64.0 million in 2015 and is expected to witness a moderate CAGR of 18.6% during the forecast period (2016 – 2024).

Figure 1. Global Artificial Pancreas Device System (APDS) Market Size and Forecast, US$ Million and Y-o-Y Growth (%), 2014–2024

Artificial Pancreas Devices System Market

Source: Coherent Market Insights Analysis (2017)

To have a snippet of the report, request Report Sample

Technological advancements to drive growth of the global artificial pancreas device system (APDS) market

In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS) MiniMed 670G which is an automated system. The continuous glucose monitor in the system automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes beyond the acceptable limit. Thus, there is no need for the user to stimulate the release of insulin every time the glucose level is abnormal. This provide the user freedom to perform his/her daily activities. Such advancement in T1D management is expected to be highly preferred by the users and medical community, leading to higher advocacy to use this device especially among the patient group using insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the Massachusetts General Hospital (Boston) and Boston University. This would further fuel the artificial pancreas device system (APDS) market growth and attract more investments.

Strategic collaborations fostering artificial pancreas device system (APDS) market growth

There were over 20 projects undertaken by the industry payers in 2015 with respect to development of artificial pancreas device system (APDS). Bigfoot Biomedical acquired Asante’s FDA approved Snap insulin pump technology in 2015 and at the same time signed a development agreement with Dexcom to integrate Dexcom’s CGM in its under development artificial pancreas device system (APDS). Dexcom is in collaboration with many other market players such as Insulet Corporation, Animas Corporation, and International Diabetes Closed Loop wherein, these companies would be incorporating Dexcom’s CGM in their artificial pancreas device system (APDS). Such collaborations are expected to expedite market entry for new artificial pancreas device system (APDS)s and thus drive the growth of artificial pancreas device system (APDS) market.

Get Discount For First Time Buyers@ https://www.coherentmarketinsights.com/insight/request-discount/79

Lack of reimbursement to hinder artificial pancreas device system (APDS) market growth

The prevalence of T1D in the U.S. is 1.35 million which is expected to increase to 5 million by 2050 as per the estimates (2016) by JDRF. Each year 40,000 people are diagnosed with T1D in the U.S. according to the JDRF. With this huge patient base, potential opportunity for artificial pancreas device system (APDS) looks considerably high at global level. However, lack of reimbursement for glucose sensors is expected to inhibit the uptake of artificial pancreas device system (APDS). With an average cost of US$ 6000-7000, adoption of artificial pancreas device system (APDS) is estimated to be restricted among rich T1D patients. Furthermore, only a few T1D patient group prefer insulin pumps for treatment. According to the 2013 report of JDRF, about 350,000 insulin pumps were sold in the U.S. Thus, creating awareness should also be an objective of artificial pancreas device system manufacturers to increase its adoption.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Rheumatoid Arthritis Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

Rheumatoid Arthritis Treatment Market Overview:

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis treatment market can be analyzed based on the drug type, as follows:

  • Biological drugs

  • Monoclonal antibodies

  • Non-Biologicals

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)

  • Corticosteroids

  • Analgesics

  • Disease-modifying anti-rheumatic drugs (DMARDs)

  • IL-6 inhibitors

  • TNF inhibitors

NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given either orally or parenterally to reduce inflammation and restore joint mobility and function. These class of drugs are more potent than NSAIDs and therefore usually preferred a first line therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be driven considerably in near future by DMARDs that form second line slow-acting therapeutic drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second line drug for RA and hence, occupies major share in the respective segment of global rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment.

Fill the form for an exclusive sample of Rheumatoid Arthritis Treatment Market report @ https://www.coherentmarketinsights.com/insight/request-sample/166

FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in pipeline would fuel the rheumatoid arthritis treatment market growth in near future.

Key statistics pertaining to the global rheumatoid arthritis treatment market:

Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient.

  • Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
  • Most common in the age group of 30-60 years
  • Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
  • Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
  • According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition
  • According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries

Plethora of research work to introduce effective treatment therapies in the global rheumatoid arthritis treatment market

Introduction of newer therapies are expected to fuel growth of rheumatoid arthritis treatment market in developed nations. Emerging economies are late adapters to new technologies and therapies, thus are potential markets for brands not yet marketed in these countries. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in pipeline include:

  • Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)
  • Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/166

More of such developments by the market players will be a significant contributor towards the growth of global rheumatoid arthritis treatment industry.

Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Gastroscopy Devices Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

Gastroscopy Devices Market Overview:

Gastroscopy is a type of endoscopy performed for diagnosis of diseases pertaining to esophagus, stomach, and upper part of small intestine. It is also called upper gastrointestinal endoscopy. It is one of the most important discoveries in the field of medical science. Esophagoscope was also a type of endoscopy that was used for diagnosis and treatment procedures of esophagus. Gastroscopy has replaced esophagoscopes completely. The only difference between esophagoscope and gastroscope is the length of gastroscope that is longer than esophagoscopes. Gastroscopy can also be performed to detect cancers. This procedure is recommended to diagnose problems related to the esophagus or stomach. The device has a light and a camera at the end of the probe that is used to see the esophagus, upper intestine and stomach clearly. It is also used to investigate problems related to swallowing, ulcers, and blockage in esophagus. This procedure allows practitioners to study the mucous membrane of the stomach. Gastroscopy are broadly classified into two types namely diagnostic gastroscopy used to diagnose or confirm diagnosis and treatment gastroscopy for therapeutic purposes. Esophagus cancer is the eighth-most common cancer in the world. As per the report of World Cancer Research Fund International, there were around 456,000 new esophagus cancer cases diagnosed in 2012. Gastroscopy is considered as the most preferred option for screening of esophagus cancer and polyps by most gastroenterologists and thus, the gastrointestinal endoscopy devices market is projected to witness significant traction in the foreseeable future.

High Incidence of Esophageal Cancer Fueling Gastroscopy Devices Market Growth

Esophageal cancer is of two types namely, adenocarcinoma and squamous cell carcinoma. Esophageal cancer can occur due to various reasons such as gene type that includes gene mutations or damage involved in cell divisions. As per results of an independent study, overweight and obesity increases the risk of esophageal cancer by 48% per 5 BMI units. Polyp detection rate of esophagus and stomach depend upon the proportion of mucosal surface diagnosed and correlates to time dedicated for diagnosis. Gastroscopes consist of a flexible tube with a high definition camera at the end of the probe. The quality of camera defines the quality of diagnosis. The long length of device is used to examine the complete length of the esophagus.

Fill the form for an exclusive sample of Gastroscopy Devices Market report @ https://www.coherentmarketinsights.com/insight/request-sample/132

Gastroscopy Devices Market: Drivers and Restraints

The global gastrointestinal endoscopy devices market is expected to be fueled by advancements in endoscopy technology. Key drivers of the market are increasing cases of esophageal cancer and polyps, growing ageing population, family history of cancer, and changing lifestyle. Increasing government initiatives to diagnose and treat early stage cancers are also expected to fuel gastrointestinal endoscopy devices market. For instance, in 2014, The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) created a community of endoscopy services across Europe, collaborating with each other to provide high quality, safe, accurate, patient-centred and accessible endoscopic care. The lack of awareness, dearth of experienced professionals, lack of reimbursement policies, and increasing cases associated with bio-dirt is expected to hinder growth of the market.

Gastroscopy Devices Market Taxonomy

The gastroscopy devices market is classified on the basis of product type and end user.

On the basis of product type, the global gastroscopy devices market is segmented into the following:

  • Flexible Video Gastroscope

  • Flexible Non-video Gastroscope

On the basis of end user, the global gastroscopy devices market is segmented into the following:

  • Hospitals

  • Ambulatory Surgical Centers

  • Clinics

Gastroscopy Devices Market: Overview

Technological advancements in gastroscopy technique are expected to drive growth of the market for gastroscopy device, as these significantly improve detection rate as compared to other conventional procedures. Practitioners prefer using flexible gastroscope over non-flexible gastroscopes due to high quality, less breakage problems and high illumination for better imaging provided by the former. Increasing awareness among practitioners of using the advanced gastroscopy over white light traditional gastroscopy is showing a significant growth towards flexible video gastroscopy. Increasing cases of biodirt provides opportunity to gastroscopy manufacturers to introduce products with innovative features to avoid such cases of infections. Hospital end user segment is expected to remain dominant in the market over the foreseeable future.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/132

Key players operating the gastroscopy devices market include Olympus, Karl Storz, Sono Scape, Endomed, Medigus, Fujifilm Holdings Corporation and Huger.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Practice Management System (PMS) Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Practice Management System Market Overview:

Practice management system (PMS) helps manage the daily operations of an organization. These systems find wide application across various verticals in an industry. Increasing investments to upgrade healthcare facilities, especially in developed regions and growth of the healthcare IT industry in developing regions, is creating a highly conducive environment for growth of the practice management systems market. Increasing adoption of PMS has been witnessed in emerging nations such as Indian, China, South Africa, and Brazil, in order to streamline operations and in turn provide better healthcare facilities in these countries. PMS allows for efficient management of health data, patient scheduling, billing process, and referral policies.

Physicians and group organizations need to maintain large amounts of data of day-to-day activities. Practice management system addresses these needs, maintaining critical patient information such as patient demographics, appointment schedule, insurance payer data, billing, and diagnostic and treatment history. Practice management system software are often synchronized with electronic medical record (EMR) or electronic health records (EMR) software for better hospital management.

Fill the form for an exclusive sample of Practice Management System Market report @ https://www.coherentmarketinsights.com/insight/request-sample/68

Practice Management Systems Market Taxonomy:

The global market is segmented as follows:

Software type:

  • Desktop-only software – intended for single or few computer sharing access

  • Client-server software – allow multiple users to share and access data, and

  • Internet-based software – do need separate server for operation

    Delivery Platform:

  • Web-based

  • Cloud

  • On-premise

    Product Type:

  • Integrated

  • Standalone

  • Components:

  • Hardware

  • Software

    End Users:

  • Physicians

  • Pharmacists

  • Diagnostic Laboratories

Increasing hospital visiting on the back of rising prevalence of Chronic and Infectious Diseases creating favorable environment for market growth

World Health Organization (WHO) estimates that there would be around 24 million cancer cases globally by 2035. In the U.S., over one-third of the adult population is obese, as revealed by statistics released by Centers for Disease Control and Prevention (CDC) (2016). As obesity is a major predisposing factor to various diseases such as diabetes and other cardiovascular diseases, steep rise in patient population is expected in the near future.

Prevalence of infectious diseases is also on the rise. Moreover, increasing instanced of drug-resistance has mandated physicians to maintain medication history of patient.

Rapid rise in geriatric population: According to WHO, over 2 billion individuals worldwide will be aged 60 years and above by 2050. A detailed report published by CDC projects that by 2030, 20% of the U.S. population would comprise of geriatric people. The report also details that cardiovascular diseases is the leading cause of deaths in adults aged 65 and above in the U.S.

Rapid rise in patients visiting hospitals mandates efficient keeping of patient history and record maintenance, in turn fueling growth of the practice management systems market.

High Installation Cost Hindering Growth in Emerging Economies

The practice management systems market share is mainly concentrated in the U.S. mainly due to presence of dense network of hospitals and existing complex healthcare service management and insurance systems. The healthcare system in the U.S., is very unlike that in other countries. Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs) have been set up, and thus patients tend to visit multiple physicians. Hence, maintenance of consistence treatment history becomes difficult. The market is also growing in major European countries such as the U.K., France, Germany, Italy, and Spain. The PMS market is yet in its introductory phase in Asia Pacific, Latin America, Africa, and Middle East regions, owing to low diagnosis and treatment rate combined with financial challenges linked with deployment of expensive software systems.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/68

Key Suppliers in the global practice management systems market: Allscripts Healthcare Solutions, Inc. Henry Schein MicroMD, Athenahealth, Inc., GE Healthcare, NextGen Healthcare Information System LLC, Practice Fusion, McKesson Corporation, Greenway Medical AdvantEgde Healthcare Solutions, MediTouch, and Accumedic Computer Systems.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Nasal Atomizer Devices Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Global Nasal Atomizer Devices Market Overview:

Nasal delivery is a choice of treatment or drug delivery for the topical treatment of nasal diseases and paranasal sinuses like sinusitis and allergic rhinitis. Moreover, the nasal route is considered in some cases over the normal oral route owing to rapid absorption and needle-free drug delivery with the effect as desired. Hence, it is also one of the preferred routes for needle-free vaccination and systemic drug delivery. Moreover, this route helps addressing issues related to poor bioavailability, slow absorption, drug degradation and adverse events in the gastrointestinal tract. Atomized nasal medications rapidly absorb across mucosal membranes into the bloodstream, avoiding first-pass metabolism. However, during nasal delivery one needs to take care to protect the delicate lungs from hazardous exposures. Medication in liquid form can be administered via nasal route through inhalers, spray pumps, droppers, nebulizers or atomizers. In atomizers the medication exits the tip as a fine atomized mist resulting in broad coverage of the nasal mucosal with a thin layer of drug.

Fill the form for an exclusive sample of Nasal Atomizer Devices Market report @ https://www.coherentmarketinsights.com/insight/request-sample/46

Nasal Atomizer Device Types

Nasal atomizers are currently used in the treatment of allergic rhinitis and sinusitis. These devices usually are multi-dose products enabling long-term usage of the device. The nasal atomizers are classified based on the technology/mechanics as gas propelled or electrical. The air or gas controlled technique involves the use of squeezed bottle which when pressed releases the content out of the small nozzle in definite volume. The dose delivered however is highly dependent on the pressure applied while squeezing the bottle. An electronic atomizer on the other hand is devised to release only a defined amount of medication from the nozzle. This makes the use of device more convenient for patients at home.

Kurve Technology had designed and developed a nasal drug delivery device called ViaNase in 2004 that used a controlled particle dispersion method. During that period, Kurve’s technology was the only known technique that delivered chemical formulations via the nose to the paranasal sinuses in clinical testing. Moreover, Kurve’s technology was also designed to be used with multiple drugs.

Accurate Dosing is Essential in Atomization

Since then there have been many new devices being introduced in the market with improving dosage accuracy. Accurate dosing is essential in a nasal atomization device to circumvent any side effects due to overdose. Recently in November 2016, Teleflex Medical Corporation recalled its MAD Nasal Intranasal Mucosal atomization device which contained drug to reverse the action of opioid overdose. The device was recalled on the warning that it may not deliver the proper dose of the drug naloxone hydrochloride. This drug with the device is extensively used by the policemen and firefighters in the U.S.

The market still in its nascent stages of adoption is experiencing increasing acceptance in the developed regions of North America and Europe. However, creating awareness among the healthcare professionals and patients is essential for acceptance of this novel technology. Increasing self-medication trend can be leveraged upon for penetrating the global nasal drug delivery devices market.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/46

Major market players include DeVilbiss Healthcare, Teleflex Incorporated, and Kurve Technology, etc. Being a niche segment of drug delivery, there exists a lot potential for manufacturers of nasal drug delivery systems.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Global Nanoparticles Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

Global Nanoparticles Market Overview:

Particles between 1 and 100 nanometers (nm) in size known as nanoparticles. An individual nanoparticle molecule behaves as a complete unit in terms of its property and transportation. Rapidly increasing public awareness for nanotechnology and introduction of new technologies will have many beneficial consequences. Moreover, increasing applications of nanotechnology in drug development and stringent guidelines for developing improved medical products are some of the prime factors which is expected to witness significant growth over the forecasted period. Furthermore, huge capital investment and high cost of nanoparticle analysis instrument is one of the key restraint for the growth of nanoparticle market. Due to its wide applications in healthcare, biomedical, electronics and among others the nanoparticle is currently a new area of research among many scientist. Rising government spending on pharmaceuticals and bio technology research and development and increasing focus on nanotechnology research also expected to experience significant growth. North America dominated the global nanoparticles market due to increasing chronic diseases such as diabetes, cardiovascular and cancer. Moreover, Europe is expected to witness the highest growth during the forecasted period, due to rapid research and development for nanoparticles. However, due to rampant economic growth of China and India, Asia Pacific is also expected to witness decent growth during the forecasted period. Furthermore, India is also an emerging hub for pharmaceuticals research and development.

Nanoparticles Market Taxonomy

On the basis of technology, the global market is classified into:

Liposomes

Nanotubes

Polymeric nanoparticles

Polymer conjugated drugs

Dendrimers

Inorganic nanoparticles

Others

On the basis of end user, the global market is classified into:

Pharmaceuticals industry

Biochemical industry

Research institutions

others

Fill the form for an exclusive sample of Global Nanoparticles Market report @ https://www.coherentmarketinsights.com/insight/request-sample/216

Nanoparticles Market Outlook – Surge in Drug Development in Pharmaceuticals Industry Augmenting Market Growth

Expansion of medical diagnostic industry and wide application of nanotechnology in healthcare sector such as neurology, cardiology and anti-infective is estimated to have a decent growth for nanoparticles market in the forecast period. Depending upon preparation methods nanoparticles, nanocapsules or nanospheres can be obtained. A long circulating particle made up of Biodegradable polymeric nanoparticles with hydrophilic polymer coating of poly ethylene glycol (PEG), used as a powerful drug delivery device. Due to its ability to deliver peptides, proteins and genes, it is also used as a DNA carrier in gene therapy. Numerous advantages for nanoparticles in drug delivery system is expected to Spector enormous growth during the forecasted period. Moreover, growing public awareness, improved technology and increase in chronic diseases escalate the global nanoparticles industry in North America. Emerging economy of Asia Pacific, such as China and India is expected to witness significant growth over the forecasted period.

Nanoparticles Market Challenges – Huge Capital Investment needed in Research and Development

Huge capital investment for research and development of new product and technology. Moreover, high cost of nanoparticles analysis instruments is expected to be one of the key restraints for global nanoparticles market.

Nanoparticles Market – Regulatory Scenario:

  • August, 2015, U.S. Food and Drug Administration (FDA), issued guidance to address various issues related to the use of nanotechnology in food ingredients intended for use in food for animals.

  • June, 2014, U.S. Food and Drug Administration (FDA), issued three guidelines related to the use of nanotechnology in regulated products, including cosmetics and food substances.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/216

Some of the key players in the market includes Abraxis Biosciences, Inc., Novartis International AG, Gilead Sciences, Inc., Johnson & Johnson, Sigma-Tau Pharmaceuticals, Inc. Amgen, Inc., and Nano Interface Technology, Inc., Malvern Instruments Ltd., Horiba Ltd., Beckman Coulter, Shimadzu Corporation, Agilent Technology Inc, Hitachi Ltd., Wyatt Technology, among others.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1-206-701-6702

E-mail:sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

BCMA Targeted Therapies market Overview:

Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma. Though, there have been recent studies that suggest a targeted effect of B-cell maturation antigen (BCMA) that has been effective in cells with multiple myelomas. BCMA is a protein, which is selectively expressed by B-lineage cells that directly work on cells with multiple myelomas. Researchers are still working to determine the compatibility in target for CAR-expressing T cells for BCMA. Furthermore, B-cell maturation antigen (BCMA) is a vital biomarker of the B-cells that is a promising and newly emerged therapeutic target to treat multiple myeloma and other hematological malignancies.

Multiple myeloma affected cells are considered to be having B-cell maturation antigen. This has led to various studies related to BCMA targeted therapies in the recent past. Multiple myeloma is the second-most common type of hematological malignancy, which affects a large population. According to the American Cancer Society, in 2017, around 30,280 new cases are estimated to be diagnosed, leading to around 2,600 deaths. Middle-aged men exposed to any type of radiation or chemicals a past history of monoclonal gammopathy of undetermined significance (MGUS) are most at risk of contracting multiple myeloma. Increasing awareness among the research community and renewed efforts across the globe to effectively treat cancer and related diseases is expected to provide major traction for growth of the BCMA targeted therapies market in the foreseeable future.

Fill the form for an exclusive sample of BCMA Targeted Therapies market report @ https://www.coherentmarketinsights.com/insight/request-sample/190

BCMA Targeted Therapies Market Taxonomy:

By Product Type

  • CAR-T cells

  • Bispecific Antibodies

  • Antibody Drug Conjugates

By End User

  • Hospitals

  • Cancer Research Institutes

Increase in prevalence of multiple myeloma globally is expected to support growth of BCMA targeted therapies market:

Multiple myeloma can be fatal and is linked with frequent events of re-occurrence of the disorder along various other serious complications associated with it. The globally widespread prevalence of the disorder and B-cell malignancies needs specific and targeted diagnosis and treatments. Hence, there is an immediate requirement for targeted and effective therapies to provide appropriate medical care. This in turn is expected to favor growth of BCMA market in the near future. Multiple myeloma is characterized by the clonal proliferation of plasma cells in bone marrow, which leads to bone destruction, renal abnormalities, anemia and hypercalcemia. The rise in prevalence of multiple myelomas in the population around the globe is projected to underpin the growth expansion of targeted therapies in BCMA market in the near future. According to National Institutes of Health and National Cancer Institute, in 2013, in the U.S., there were around 96,000 people living with myeloma.

Specificity and targeted effect on cancer cells is projected to favor growth of the BCMA targeted therapies market

B cell maturation antigen, is the member of the tumor necrosis factor receptor group and a type III membrane protein containing one extracellular cysteine rich domain, which has been designated as TNFRSF17. The specificity of the therapy to treat the patients affected from multiple myelomas is projected to be one of the vital factors favoring growth in adoption of B-Cell Maturation Antigen targeted therapies in the near future. Furthermore, collaboration between the existing players in the B-Cell Maturation Antigen market is expected to be one of the crucial factor in its growth, this will further expected to enhance the company’s product portfolio over the forecast period.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/190

Key players operating in the BCMA targeted therapies market include Celgene Corporation, bluebird bio, Poseida Therapeutics, Inc., Juno Therapeutics, Eureka Therapeutics,

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1-206-701-6702

E-mail:sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com